Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Latest Pharmaceuticals and Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals, Inc. Stock News

As of July 31, 2026, Corcept Therapeutics Incorporated had a $12.4 billion market capitalization, compared to the Pharmaceuticals median of $579.1 million. Corcept Therapeutics Incorporated’s stock is up 229% in 2026, up 20.1% in the previous five trading days and up 63.77% in the past year.

Currently, Corcept Therapeutics Incorporated’s price-earnings ratio is 252.2. Corcept Therapeutics Incorporated’s trailing 12-month revenue is $830.8 million with a 6.6% net profit margin. Year-over-year quarterly sales growth most recently was 31.7%. Analysts expect adjusted earnings to reach $2.280 per share for the current fiscal year. Corcept Therapeutics Incorporated does not currently pay a dividend.

As of July 31, 2026, Amphastar Pharmaceuticals, Inc. had a $879.2 million market cap, putting it in the 44th percentile of all stocks. Amphastar Pharmaceuticals, Inc.’s stock is down 25.5% in 2026, up 6.5% in the previous five trading days and down 6.56% in the past year.

Currently, Amphastar Pharmaceuticals, Inc.’s price-earnings ratio is 12.0. Amphastar Pharmaceuticals, Inc.’s trailing 12-month revenue is $720.5 million with a 11.0% net profit margin. Year-over-year quarterly sales growth most recently was 0.4%. Analysts expect adjusted earnings to reach $2.557 per share for the current fiscal year. Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
Corcept Therapeutics Incorporated	CORT	A
Amphastar Pharmaceuticals, Inc.	AMPH	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Corcept Therapeutics Incorporated has a Growth Score of 89, which is Very Strong. Amphastar Pharmaceuticals, Inc. has a Growth Score of 83, which is Very Strong.

The Growth Grade Winner: It’s a Tie!

Looking at the Growth Grade breakdown above, both Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc. have a grade of A. For investors who focus solely on a company’s upward growth, further research should be conducted into both companies’ other financial metrics before deciding whether to invest.

Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Corcept Therapeutics Incorporated	CORT	A
Amphastar Pharmaceuticals, Inc.	AMPH	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Corcept Therapeutics Incorporated has a Momentum Score of 98, which is Very Strong. Amphastar Pharmaceuticals, Inc. has a Momentum Score of 33, which is Weak.

The Momentum Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Momentum Grade breakdown above, Corcept Therapeutics Incorporated is considered to have stronger momentum compared to Amphastar Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Corcept Therapeutics Incorporated	CORT	B
Amphastar Pharmaceuticals, Inc.	AMPH	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Corcept Therapeutics Incorporated has a Earnings Estimate Score of 78, which is Positive. Amphastar Pharmaceuticals, Inc. has a Earnings Estimate Score of 11, which is Very Negative.

The Earnings Estimate Revisions Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Corcept Therapeutics Incorporated has a better Earnings Estimate Revisions Grade than Amphastar Pharmaceuticals, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc. Grades

In addition to Growth, Momentum and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals or Inc. Stock?

Overall, Corcept Therapeutics Incorporated stock has a Growth Score of 89, Momentum Score of 98 and Estimate Revisions Score of 78.

Amphastar Pharmaceuticals, Inc. stock has a Growth Score of 83, Momentum Score of 33 and Estimate Revisions Score of 11.

Comparing Corcept Therapeutics Incorporated, Amphastar Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.